Top Markets
#1 Helium Helium +47.69%
#2 Pons Pons +39.28%
#3 TENDIES TENDIES +29.66%
#4 pipedog pipedog +23.35%
#5 Seeker Seeker +21.59%
#6 UnifAI Network UnifAI Network +19.17%
#7 Bounce Bounce +17.09%
#8 Songbird Songbird +12.58%
#9 Cysic Cysic +10.52%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +10.49%
Coin of the day
Helium Helium
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Shanghai Haohai Biological Technology Co., Ltd. Shanghai Haohai Biological Technology Co., Ltd.

Shanghai Haohai Biological Technology Co., Ltd.

688366
Classifica tra le azioni #10462
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise... Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and distribution of advanced biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various international markets. The company's extensive product portfolio serves multiple medical fields. For ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, specialized orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. In orthopedics, they provide sodium hyaluronate injections and medical chitosan. Their wound care segment features recombinant human epidermal growth factor, effective in treating a broad spectrum of injuries, including burns, residual wounds, donor site trauma, post-traumatic wounds, and both acute and chronic ulcerations. Anti-adhesion solutions are offered in the form of medical sodium hyaluronate gel and medical chitosan, while hemostatic products include collagen sponges and porcine fibrin sealants. Within medical aesthetics, Shanghai Haohai produces a diverse range of hyaluronic acid (HA) dermal fillers: Matrifill, a first-generation mono-phase injectable gel; Janlane, a second-generation filler engineered for dynamic applications; and Hyalumatrix, a third-generation product designed for precise aesthetic enhancements. This division also supplies radio frequency devices and laser equipment. Beyond its core product offerings, the company actively pursues research and development in biological engineering and pharmaceutical innovations. It also provides related technology transfer and consultation services, alongside engaging in investment and trading activities. Originally established in 2007 as Haohai Limited, the company adopted its current name, Shanghai Haohai Biological Technology Co., Ltd., in 2010 and is headquartered in Shanghai, China.
Prezzo delle azioni
$4.39
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$835.72M
Variazione (1 giorno)
0.33%
Variazione (1 anno)
-42.81%
Paese
CN
Scambia Shanghai Haohai Biological Technology Co., Ltd. (688366)

Categoria

Healthcare
Ricavi di Shanghai Haohai Biological Technology Co., Ltd. (688366)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Shanghai Haohai Biological Technology Co., Ltd., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Shanghai Haohai Biological Technology Co., Ltd. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH